ZIA CP004410 08090 (ZIA) | |||
---|---|---|---|
Title | CLL Families | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Caporaso, Neil | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $268,110 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Agent Orange/Dioxin Related (10.0%) Biochemical Epidemiology (45.0%) Cancer (100.0%) |
Leukemia (100.0%) | ||
Research Type | |||
Endogenous Factors in the Origin and Cause of Cancer Interactions of Genes and/or Genetic Polymorphisms with Exogenous and/or Endogenous Factors |
|||
Abstract | |||
In this family study, we conduct diverse genetic and biomarker studies in CLL kindreds. We recruit new families via referral, newsletter contact with existing families as well as routine follow-up, and letters sent to the membership of professional societies such as the American Society of Hematology (ASH). The last letter was sent in May 2011 to 6500 members. Five new families were referred to the CLL study as a aresult of the ASH mailing. Data collection and data management are ongoing activities. A FAIR Module captures study specific information, including flow cytometry data, used to ascertain the diagnosis and identify the precursor condition, MBL or monoclonal B cell lymphocytosis. During the last year we described the features of MBL observed in CLL kindreds and in a seperate publication, described molecular features of MBL. These studies are being extended to other lymphoproliferative families. A variety of genetic studies are in progress in the CLL kindreds including GWAS (in collaboration with the Genetic Epidemiology of CLL Consortium), epigenetics (methylation status), and exome and whole genome sequencing in selected kindreds. A study of possible viral involvement using high throughput sequencing of tumor and non-tumor cells from selected familial affecteds is in progress. A study of mosaic abnormalities in GENEVA and with CGR has identified chromosome 13 abnormailies in CLL patients, and we are conducting follow-up in familila and population-based CLL subjects. |